Cabot Corporation $CBT Shares Purchased by Blue Trust Inc.

Blue Trust Inc. lifted its stake in shares of Cabot Corporation (NYSE:CBTFree Report) by 15.6% during the 2nd quarter, HoldingsChannel reports. The firm owned 5,713 shares of the specialty chemicals company’s stock after purchasing an additional 769 shares during the quarter. Blue Trust Inc.’s holdings in Cabot were worth $428,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in CBT. Geneos Wealth Management Inc. boosted its holdings in shares of Cabot by 409.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 453 shares of the specialty chemicals company’s stock worth $38,000 after purchasing an additional 364 shares during the last quarter. Banque Cantonale Vaudoise acquired a new position in Cabot during the first quarter worth $43,000. CWM LLC boosted its stake in Cabot by 55.0% during the first quarter. CWM LLC now owns 600 shares of the specialty chemicals company’s stock worth $50,000 after buying an additional 213 shares during the last quarter. UMB Bank n.a. boosted its stake in Cabot by 52.4% during the second quarter. UMB Bank n.a. now owns 730 shares of the specialty chemicals company’s stock worth $55,000 after buying an additional 251 shares during the last quarter. Finally, Brooklyn Investment Group boosted its position in shares of Cabot by 1,553.7% during the 1st quarter. Brooklyn Investment Group now owns 678 shares of the specialty chemicals company’s stock valued at $56,000 after acquiring an additional 637 shares during the last quarter. 93.18% of the stock is currently owned by institutional investors and hedge funds.

Cabot Price Performance

Cabot stock opened at $69.59 on Tuesday. The company’s 50 day simple moving average is $78.05 and its 200-day simple moving average is $77.05. The company has a market capitalization of $3.70 billion, a price-to-earnings ratio of 9.10 and a beta of 0.88. Cabot Corporation has a 1 year low of $69.04 and a 1 year high of $117.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 2.13.

Cabot (NYSE:CBTGet Free Report) last announced its earnings results on Monday, August 4th. The specialty chemicals company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. Cabot had a return on equity of 25.68% and a net margin of 11.14%.The company had revenue of $923.00 million for the quarter, compared to analyst estimates of $957.29 million. Cabot has set its FY 2025 guidance at 7.150-7.500 EPS. As a group, equities research analysts expect that Cabot Corporation will post 7.57 earnings per share for the current year.

Insider Activity

In related news, CEO Sean D. Keohane sold 114,436 shares of the business’s stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $79.28, for a total value of $9,072,486.08. Following the sale, the chief executive officer owned 361,518 shares in the company, valued at approximately $28,661,147.04. The trade was a 24.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 3.03% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on CBT shares. Weiss Ratings reissued a “hold (c)” rating on shares of Cabot in a research report on Wednesday, October 8th. Mizuho decreased their target price on shares of Cabot from $90.00 to $88.00 and set an “outperform” rating on the stock in a report on Friday, October 3rd. Finally, UBS Group set a $82.00 price objective on Cabot and gave the company a “neutral” rating in a report on Tuesday, August 5th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Cabot currently has a consensus rating of “Hold” and a consensus target price of $85.00.

View Our Latest Report on CBT

Cabot Company Profile

(Free Report)

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.

Featured Stories

Want to see what other hedge funds are holding CBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cabot Corporation (NYSE:CBTFree Report).

Institutional Ownership by Quarter for Cabot (NYSE:CBT)

Receive News & Ratings for Cabot Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabot and related companies with MarketBeat.com's FREE daily email newsletter.